In-vitro activity of arbekacin alone and in combination with vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureus

Diagn Microbiol Infect Dis. 2000 Jan;36(1):37-41. doi: 10.1016/s0732-8893(99)00104-2.

Abstract

In-vitro susceptibility studies were performed on 99 clinical Staphylococcus aureus isolates. A total of 68 of 73 methicillin-resistant S. aureus and 2 of 26 methicillin-susceptible S. aureus were gentamicin-resistant (gentamicin MIC range 16 to 1,024 microg/mL). All 70 gentamicin-resistant isolates contained the aac(6')-Ie-aph(2'')-Ia aminoglycoside resistance gene, and none possessed the aph(2'')-Ic or aph(2'')-Id aminoglycoside resistance genes. The arbekacin MIC for the 70 gentamicin-resistant isolates ranged from 0.25 to 4 microg/mL. The combination of arbekacin plus vancomycin produced synergistic killing against 12 of 13 gentamicin-resistant MRSA isolates. The combination of gentamicin plus vancomycin produced synergistic killing against 7 of the same 13 isolates. Arbekacin may prove useful when used in combination with vancomycin in treating infections caused by gentamicin-resistant MRSA.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminoglycosides*
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / pharmacology
  • Base Sequence
  • DNA, Bacterial
  • Dibekacin / administration & dosage
  • Dibekacin / analogs & derivatives*
  • Drug Interactions
  • Drug Resistance, Multiple*
  • Drug Therapy, Combination / pharmacology*
  • Gentamicins / pharmacology*
  • Humans
  • Methicillin Resistance*
  • Microbial Sensitivity Tests
  • Molecular Sequence Data
  • Polymerase Chain Reaction
  • Sensitivity and Specificity
  • Staphylococcus aureus / drug effects*
  • Staphylococcus aureus / isolation & purification
  • Vancomycin / administration & dosage*

Substances

  • Aminoglycosides
  • Anti-Bacterial Agents
  • DNA, Bacterial
  • Gentamicins
  • Dibekacin
  • Vancomycin
  • arbekacin